Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Keywords: ATP-competitive mTORC1/2 inhibitors; Abraxane; Advanced gastric cancer; Advanced low-tointermediate grade neuroendocrine tumors (LGNETs); Advanced solid tumors (ovarian, uterine, colorectal, pancreatic, and head and neck cancers); Akt/PKB (protein kinase B); Cancer clinical trials; DNA damage; Dual PI3K-mTOR inhibitors; Everolimus; Everolimus Octreotide (somatostatin analog) LAR (long-acting repeatable); Everolimus trastuzumab (anti-HER2 agent) paclitaxel; FKBP12; FKBP12-rapamycin binding; FRB; HER2-positive metastatic breast cancer; MCL; NEC; Nab-rapamycin; PIP2; PIP3; PTEN; Phosphatase and tensin homolog deleted on chromosome ten; RCC; Rapamycin (Sirolimus); Rapamycins; Raptor; Recurrent malignant glioma; Ridaforolimus; Ridaforolimus bevacizumab (anti-VEGF agent); Ridaforolimus trastuzumab (anti-HER2 agent); S6K1 gene; Sirolimus gefitinib (anti-EGFR agent); Streptomyces hygroscopicus; TSC (tuberous sclerosis protein complex); TSC1 (hamartin)/TSC2 (tuberin); albumin-bound nabTM-paclitaxel; amino acids, glucose; angiogenesis; colorectal cancer; hepatocellular cancer (HCC); heterodimer; insulin, IGF1; mLst8/GL; mSin1; mSin2; mTOR; mTOR-targeted therapeutics; msin3/Rictor; neuroendocrine cancer (NEC); oxidative; pancreas (adenocarcinoma); phosphatidylinositol 3-kinase (PI 3-kinase)-related kinase (PIKK); protor; ribosome biogenesis; sarcoma; serine/threonine kinase; sirolimus
Document Type: Research Article
Publication date: January 1, 2011
- Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.
The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites